I wonder if any gamblers noticed my post 334 on the GMC thread yesterday.
It looks as though bottom fishing can sometimes pay off.

This looks one of the biggest punts around, based mainly on one single win or bust treatment, but the chart says 20p pdq. Considering a gamble.
Any chance of some charts in the header, thanks for flagging it up squidd, even if i am a tad late in noticing the potential!

hawick: This chart gives the latest picture, though I usually work on a series of Sharescope charts which I find gives a more comprehensive picture, and suggested to me back in March that this was a classic recovery scenario.

moneyplus: Looking at the above mentioned charts for MDY, it looks to me as if it's still in downtrend and hasn't bottomed yet. Worth keeping on the watch list though.
sd.

ELA seems to be gathering momentum, now up 60% since 1st Nov and 25% this month. It has overtaken everything else in my portfolio, even PMK, as my Winter front runner. I think the chairman must have known something about re-approval of Tsybari when he made that hefty share purchase 3 months ago.
Hope there are many of on board.
sd.

And up another 7% on opening this morning; wish I could dig up some news.
sd.

Thanks Squidd, my chart analysis still says 20, after a very brief pause on the way up around 15. Timing is hard but the chart has certain similarities to PMK (I said 25p on it when it was 10p and did nothing about it!), Good luck.

hawick: I agree with you on the chart forecast, but look also at the 10year chart, could ELA return to the glory days of 40? They have streamlined their operations and have a good pipeline of new drugs led by Tsybari; and the pharma industry as a whole must be encouraged by the failure so far of the Vioxx litigants to screw Merck. Even higher risk now it's so far off the bottom, but I'm still buying.
Horrified to hear you didn't get into PMK.

In recent weeks, 2 other drugs that treat MS, one based on on cannabis and the other on goats milk, have had to be withdrawn owing to side effects. Increasingly, Tsybari is emerging as the only treatment for MS and various other illnesses and should it be re-approved, it will undoubtedly be a blockbuster so propelling ELA to new heights.
Meanwhile, a year end spurt in the sp made ELA my top performer of 2005, beating the likes of ULT, AEX and CSB. More to come in 2006 I'm thinking.
Prosperous New Year to all,
sd.

ELA continues its steep climb and is still leading the pack.

Well and truly filling the gap to E20.

Hawick, can you explain 'E20' please

Hampi - filling the gap to 20 euros I guess.

Cheers Frampton, spot on, I haven't got the Euro symbol on keyboard!

AFX news on yahoo finance, reports from the JP Morgan Annual Healthcare Conference held on Wed 11 January, about progress towards re-approval of Tysabri to treat MS. It re-iterates the view that Tysabri is superior to other treatments and implies that re-approval is just a formality, awaiting only agreement with the FDA on new labelling to warn of the side effects of immuno-suppressor drugs. It is envisaged that Tysabri will be back on the market by the middle of this year.
.

Even on a miserable day everywhere else, ELA is still climbing.
There is chatter on the other side of it being tipped in a US tip sheet.

I bought 500 of these at 3.47 euros last april, there was never a chance of tysabri not coming back it was ust a question of when (having taken the drug myself). The latest webcasts all but announce its return. Pharmacutical equities seem to have a life of their own. Last night their trading in NY set new 52 week high. Think I should be selling around the 24 euro mark in march time, although they do have promising work for altsheimers disease, so perhaps i should hang on to them even after a tysabri relaunch? Decisions decisions!

not 52 week high meant year sorry

And today some really smart NY analyst says he doesnt think tysabri will be perscribed by doctors very widely! causing mass panic with elan shares, and they drop 1.5 euros! I mean does this guy know anything about MS? obviously not otherwise he would know Tysabri is at least twice as effective against relapses than any other therepy out there not only that but it also promotes the brain to heal itself meaning a reversal of disability, sounds like a wonder drug? Well I for one know that to be true and in the nightmare world of brain demylination I know the MS community would all gladly take this drug, rather than suffer a slow degeneration of every human function.

So its not a question of wether the docs will perscribe this therepy, but just how fast the patients suffering can get it. take it from me buy this stock, it may take a while to prove the critics wrong but when the profits are announced in a few months time you will probally wonder why you never invested in Elan when they were so cheap.

Crippy: Thanks for your posts. It's amazing that you have experience of Tysabri as I didn't think it had been trialled over here, and my own reading on its value suppports what you have to say. The dip sets back the recovery only by about two weeks as far I can see and I think offers an opportunity to top up. If only I had some spare funds. Meanwhile there is chatter on the other side about Elan's partnership with Wyeth to develop two drugs for Alzheimers, which they say could be very, very big.

Yes squidd i was on the European mono therepy trial here for a couple of years. You could say i am living proof of why the drug is so good. According to the doctors eho were overseeing the trial the problems the drug encountered only occured when used in conjunction with other immunosuppressants, because on its own it is ultra effecient at doing its job. So when combined with other drugs of a similar nature it is to heavy a load for some peoples immune systems to deal with. Hence the only deaths occurred when the drug was being prescribed wrongly. As I am sure you are aware, american doctors are essentially drugs sales people for the various pharma companies, and when a patient asks for a drug they generally get it. With Tysabri it was a shame because 2 people died because they suppressed their immune systems too much, I supose this is a testemant too Tysabris effectiveness, and also shows how poor other MS therepys are because doctors were used to perscribing multiple therepies before because the drugs previously available didnt work very well.

Interesting to hear about the Alzheimers drug, think I may have to scrape together some pennies to up my stake in elan me thinks.

ELA firmly back on the recovery trail after reporting results ahead of market expectations on 31st Jan - even without any contribution from Tysabri, for which they are planning a high profile relaunch in the US, hopefully in the next couple of months. My reading of the newsflow is that the market has yet to price in the likely impact of the new Altzheimer treatments.